The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.
Lynette Isabella Ochola-Oyier;
John Okombo;
Leah Mwai;
Steven M Kiara;
Lewa Pole;
Kevin KA Tetteh 
;
Alexis Nzila;
Kevin Marsh;
(2014)
The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.
Antimicrobial agents and chemotherapy, 59 (3).
pp. 1770-1775.
ISSN 0066-4804
DOI: 10.1128/AAC.03522-14
;
Alexis Nzila;
Kevin Marsh;
(2014)
The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.
Antimicrobial agents and chemotherapy, 59 (3).
pp. 1770-1775.
ISSN 0066-4804
DOI: 10.1128/AAC.03522-14
The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P = 0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).
-
picture_as_pdf - zac1770.pdf
-
subject - Published Version
-
- Available under Creative Commons: 3.0
Downloads